Eurofins Agroscience Services has acquired Selcia Limited, a leading provider of custom radiolabelling and integrated drug discovery services. 

This acquisition adds another important service to the Agroscience portfolio; from its radiolabelling services business, Selcia produces custom radiolabelled compounds incorporating carbon-14 for the pharmaceutical, agrochemical, biotech, life sciences and chemical industries.  These carbon-14 (14C) radiolabeled compounds are used to support a wide range of critical regulatory, REACH and research studies.

Selcia brings a profound knowledge, expertise and experience to the Agroscience division, further strengthening an already comprehensive offering of services to support regulatory submissions of agrochemicals and biocides. 

Klaus Kuegler, Senior Vice President of Eurofins Agroscience Services Group, comments, “We are extremely pleased to welcome Selcia to the Eurofins Group. Selcia’s focus on quality, with GLP analytical and GMP 14C API manufacturing, and world leading 14C radiolabelling capabilities fills a strategic gap in Eurofins’ global offering in the highly attractive pharmaceutical and Agroscience testing markets. In addition, Selcia provides Eurofins with integrated drug discovery services with a track record of delivering preclinical candidates.  We look forward to supporting Selcia’s growth by providing access to the full range of services and capabilities of the Eurofins Group.”

Clive Cornell, Chief Operating Officer, at Selcia adds, “Selcia is excited to become an integral part of the Eurofins Group. The acquisition will help Selcia invest and grow to meet the increasing global demand for high quality, carbon-14 radiolabelled compounds which are used to facilitate both traditional and modern cross-sector regulatory studies, such as environmental fate, dermal penetration, drug metabolism, human mass balance and absolute bioavailability.  Importantly Selcia will continue to independently foster relationships with new and existing customers as well as with Eurofins’ worldwide network of laboratories. In addition, the acquisition enables Eurofins Pharma Discovery Services to provide a more comprehensive offering of integrated drug discovery services. These include innovative hit to lead and lead optimisation medicinal chemistry, supported by internal assay development and screening including Selcia’s unique peptidyl prolyl isomerase services.“